Figure 2. MAPK/ERK signaling mediates the pro-proliferative effect of oncogenic KRAS.
(A) IEC-iKRAS cells were treated with or without 5 mM IPTG for 48 h. Fifty μM PD98059 or DMSO (vehicle control) were added 24 h following the addition of IPTG. Western blot analyses were performed using KLF5, phospho-ERK (p-ERK) and ERK antibodies. (B) Cell proliferation was measured under the treatment conditions depicted in the panel. N = 6; * p < 0.05 when compared to DMSO-treated cells.